Plasmodium immunotherapy for cancer - CAS Lamvac Biotech

Drug Profile

Plasmodium immunotherapy for cancer - CAS Lamvac Biotech

Alternative Names: Plasmodium cancer vaccine - CAS Lamvac Biotech

Latest Information Update: 15 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Guangzhou Institutes of Biomedicine and Health
  • Developer CAS Lamvac Biotech; State Key Laboratory of Respiratory Disease
  • Class Antineoplastics; Cancer vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-small cell lung cancer

Most Recent Events

  • 26 May 2016 Phase-I/II clinical trials in Non-small cell lung cancer in China (Parenteral) (NCT02786589)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top